Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Oxford Immunotec announces contract with Scancell to measure T cell response in immunotherapy trial

Oxford Immunotec announces contract with Scancell Ltd to measure T cell response in Phase I/II clinical immunotherapy trial.

Oxford, UK and Marlborough, MA; 23rd March 2010 – Oxford Immunotec Ltd, the T cell measurement company, today announces that it has signed a contract with Scancell Ltd to provide services in support of Scancell’s Phase I/II clinical trial with SCIB1 Scancell’s DNA ImmunoBody® vaccine for the treatment of melanoma. Under the contract, Oxford Immunotec will utilize its ELISpot technology to measure T cell responses to SCIB1.

Scancell’s immunotherapy is designed to generate the high-avidity T-cells that kill cancer cells. Oxford Immunotec’s laboratory will provide T cell separation, cryo-preservation and the ELISpot assays required by Scancell to measure T cell responses to SCIB1.

Commenting on the collaboration, Dr Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec, said, “As our understanding of human immune biology progresses, we expect to see an increasing number of innovative approaches that elicit response from the cellular components of the immune systems, in particular T cell responses. Monitoring of T cell responses in trials such as Scancell’s melanoma immunotherapy trial will become increasingly important in correlating therapeutic effects of new products on the immune system and clinical end points.”

Professor Lindy Durrant, Chief Executive Officer of Scancell Ltd., stated, “We were impressed with Oxford Immunotec’s ELISpot expertise and systems and are delighted to use the company’s services for this critical assay in the assessment of safety and efficacy of our lead ImmunoBody® vaccine, SCIB1”.

Notes to Editors:

About Oxford Immunotec
Oxford Immunotec Ltd., the T cell measurement company, is headquartered near Oxford, UK; its US operations are based in Marlborough, MA. The company develops and sells clinical diagnostic products based on its patented T-SPOT® technology, the first FDA-approved method for directly quantifying antigen-specific T cells.

T-SPOT technology is a simple and extremely accurate method of studying a person’s cellular immune response to infection and could be applied to diagnose and monitor any major disease driven by a T cell response.

About Scancell
Scancell is developing novel therapeutic vaccines for the treatment of cancer and infectious diseases based on its groundbreaking ImmunoBody® technology platform. Scancell’s first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and will enter clinical trials in 1H 2010.

ImmunoBody® is a DNA vaccine encoding a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour antigens as they can effectively target dendritic cells via their Fc receptors, allowing efficient stimulation of high avidity and high frequency helper and CTL responses.

The ImmunoBody® technology can be adapted to provide the basis for treating any tumour type and may also be of potential utility in the development of vaccines against hepatitis, HIV and other chronic infectious diseases.

Professor Lindy Durrant
Tel: + 44 207 245 1100
Scancell Limited
Department of Clinical Oncology
City Hospital
Hucknall Road

PR Agent:
Kirsty Corcoran/John Bick
Hansard Communications
Tel: + 44 207 245 1100 Fax: +44 207 245 0909

At Oxford Immunotec:
Dr Peter Wrighton-Smith, CEO
Tel: +44 (0)1235 442780
Fax: +44 (0)1235 442781

Oxford Immunotec
94c Milton Park
Oxfordshire OX14 4RY, UK

Oxford Immunotec Inc,
2 Mount Royal Avenue,
MA 01752, USA

Publisher Contact Information:

Oxford Immunotec Ltd.
+44 (0)1235 442780

Company profile of Oxford Immunotec Ltd.
Past press releases of Oxford Immunotec Ltd..


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Jul 31€2.8MInternet services
Jul 30€9.5MWireless applications
Jul 30€4.5MSensors
Jul 30€5.0ME-Commerce
Jul 30N/ANetwork management
Jul 30€72.0MInternet services

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.